FCGR2A and neoplasm: Furthermore, for an agonistic anti-death receptor antibody with intrinsic anti-tumor activity that is potentiated by FcγR interactions, effector cells expressing the higher-binding CD16A and CD32A variants supported substantially greater proapoptoptic activity [19].